Pharma

Your Article Summary

See Latest Articles

Morphotek, Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Morphotek, 07/08/09

Morphotek, Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.

Today in M&A/Partnerships...keeping you current

Receive free subspecialty "5-minute updates" via email

Array BioPharma and Amgen Partner in Type 2 Diabetes
Amgen, 12/15/09

Inno Biologics and CEVEC Sign License Agreement for Human CAP Technology
b3c newswire, 12/09/09

Federal Advisory Committees to Meet
HealthDataManagement, 12/09/09

 See all of M&A/Partnerships

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
GlaxoSmithKline, 12/15/09

New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer
Genentech, 12/15/09

GSK and Intercell form strategic alliance to develop and commercialise innovative needle-free patch-based vaccines
GlaxoSmithKline, 12/15/09

 See all of Research & Development